Follow

Calmark brings forward publication of interim report for Q3

27 October 2021 - 17:55

Calmark Sweden AB (publ) announces today that the publication of the interim report for the third quarter of 2021 will be further brought forward to 29 October.

The work to complete the report for the third quarter has gone faster than planned, which is why the Board today decided to bring forward the report for another week to 29 October, from the previously communicated date of 5 November. This also enables appropriate trading before the record date for the rights issue decided on 22 October. The last day for trading including the right to participate in the rights issue is 3 November 2021.


Every care has been taken in the translation of this document. In the event of discrepancies, the Swedish original will supersede the English translation.
 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: [email protected] 
www.calmark.se 

Calmark Sweden AB is a medical technology company that develops and markets a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark sells a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.  

Provided by: Cision
Spotlight Stock Market (Sweden)
Calmark Sweden AB
Calmark is specialised in the development of diagnostic equipment for infants. The technology is based on a proprietary platform and is used for analysis during the first weeks after birth. The instrument is used as a biomarker to study blood count....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More